Primary Open-angle Glaucoma
Conditions
Brief summary
An interventional, open, prospective, multi-center pre-market clinical investigation according to §§20-23a Medizinproduktegesetz (MPG, medical devices act), in which a total of 40 eyes of 40 consecutive patients at up to five (5) clinical sites will be enrolled, treated with the VISULAS green with option CSLT, and followed for a three months period. The primary objective of this clinical investigation is to evaluate safety and effectiveness of SLT with the VISULAS green laser with option CSLT.
Interventions
Treatment will be performed on Day 0 using the VISULAS green with Option CSLT for SLT treatment and a mirror goniolens to visualize the trabecular meshwork. The initial energy level is set according to the grade of angle pigmentation and bubble formation. Approximately one hundred non-overlapping lesions will be applied in a single session to 360° of the trabecular meshwork.
Sponsors
Carl Zeiss Meditec AG
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Males and females at least 22 years of age or older, primary open-angle glaucoma (HPG + NPG), who did not reach target pressure . * IOP with or without medications ≥17 mmHg in the study eye * Chamber angle Shaffer 3 and 4 * Patients must be legally competent and able to give consent and must have read, understood and signed patient information leaflet and consent to undergo SLT in one eye * Patients are willing and able to return for follow-up examinations * In the opinion of the investigator, the patient will be compliant and have a high probability of completing the clinical investigation and all required procedures
Exclusion criteria
* Corneal disease or pathology in a way that distortion of laser light in the study eye can be expected or that precludes stabilization of the cornea by the contact glass, visibility of the trabecular meshwork or transmission of laser wavelength * Strong clouding of the anterior ocular media (e.g. the lens due to dense cataract) and the vitreous body (e.g. due to strong vitreous hemorrhage) in either eye * Deep orbits and/or narrow palpebral fissures * Corneal or conjunctival abnormality precluding contact lens adaptation in either eye * History of Amblyopia in either eye * Any contraindications to SLT in study eye. * Any kind of planned ocular surgeries during the next 3 months (for example, cataract surgery) in either eye * Previous intraocular or corneal surgery of any kind (except cataract surgery longer than three months prior to the clinical investigation), including surgical glaucoma intervention in study eye before the clinical investigation. * Signs of Fuchs' Dystrophy (e.g. corneal endothelial guttata) in either eye * Active or history of Uveitis in either eye * Congenital glaucoma in either eye * Diabetic retinopathy or branch retinal vein occlusion with the risk to develop neovascularizations in either eye * Heavily pigmented trabecular meshwork due to pseudoexfoliation syndrome or pigment dispersion glaucoma in either eye * Degenerative disorders of the central nervous system if it prevents proper compliance or the ability to undergo the tests in the clinical investigation (e.g. Parkinson Disease, Alzheimer Disease, or other forms of dementia) * History of or has a current, clinically significant major psychiatric disorder (e.g., major depressive disorder, psychosis, schizophrenia) * Patients who are pregnant, lactating, or of child-bearing potential and not practicing a medically approved method of birth control. * Enrollment in another drug or device study within the prior 3 months
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| mean absolute change in intraocular pressure (IOP) compared to baseline at month 1 | one (1) month | The endpoint is the mean change in IOP (Absolute value, mmHg) of the study cohort compared to baseline at month 1 |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| mean relative change in intraocular pressure (IOP) compared to baseline at month 1 | one (1) month | The endpoint is the mean change in IOP (relative value, %) of the study cohort compared to baseline at month 1 |
| mean absolute change in intraocular pressure (IOP) compared to baseline at month 3 | three (3) months | The endpoint is the mean change in IOP (Absolute value, mmHg) of the study cohort compared to baseline at month 3 |
| mean relative change in intraocular pressure (IOP) compared to baseline at month 3 | three (3) months | The endpoint is the mean change in IOP (relative value, %) of the study cohort compared to baseline at month 3 |
Other
| Measure | Time frame | Description |
|---|---|---|
| Rate of intraoperative Adverse Device Effects | one (1) day | Outcome Parameters Safety: Rate of intraoperative Adverse Device Effects |
| rate of patients achieving >0 to <10% IOP reduction from baseline | three (3) month | The following exploratory endpoint will be determined additionally: \- rate of patients achieving \>0 to \<10% IOP reduction from baseline at 1 and 3 months |
| Rate of Adverse Events and Severe Adverse Events | three (3) month | Outcome Parameters Safety: Rate of Adverse Events and Severe Adverse Events over the entire course of the clinical investigation |
| Rate of Adverse Device Effects and Device Deficiencies | three (3) month | Outcome Parameters Safety: Rate of Adverse Device Effects and Device Deficiencies over the entire course of the investigation |
| rate of patients achieving 10% to <20% IOP reduction from baseline | three (3) month | The following exploratory endpoint will be determined additionally: \- rate of patients achieving 10% to \<20% IOP reduction from baseline at 1 and 3 months |
| rate of patients achieving ≥20% IOP reduction from baseline | three (3) month | The following exploratory endpoints will be determined additionally: \- rate of patients achieving ≥20% IOP reduction from baseline at 1 and 3 months. |
| Post-operative intraocular pressure (IOP) in mmHg | one (1) day | Outcome Parameters Safety: Post-operative intraocular pressure (IOP) in mmHg: 1h, 1d |
Countries
Germany
Outcome results
None listed